{
  "id": 1535092,
  "title": "LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer",
  "url": "https://urgent.news/2026/08/17/lynkuet-elinzanetant-receives-expanded-market-authorization-in-canada",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T18:24:07.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/lynkuet-elinzanetant-receives-expanded-market-authorization-in-canada-for-treatment-of-moderate-to-severe-vasomotor-symptoms-caused-by-adjuvant-endocrine-therapy-aet-related-to-breast-cancer"
  },
  "original_language": "en",
  "account": null,
  "summary": "Expanded authorization introduces a treatment option for women experiencing moderate to severe hot flashes and/or night sweats caused by adjuvant endocrine therapy (AET) related to breast cancer LYNKUET® is the first NK-1 and NK-3 receptor antagonist indicated in the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause Expanded indication is supported by […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}